title: Utility of the triazole D0870 in the treatment of experimental systemic coccidioidomycosis.
abstract: The new triazole, D0870, was tested for therapeutic efficacy in the treatment of experimental systemic murine coccidioidomycosis. D0870 at 1 or 10 mg kg-1 daily, or 10 or 100 mg kg-1 every other day, and fluconazole at 100 mg kg-1 daily prolonged survival (P < 0.01), but were equivalent to each other. D0870 at 10 mg kg-1 daily or 100 mg kg-1 every other day cured 20 or 30% of mice of residual infection, respectively, and were superior to 100 mg kg-1 of fluconazole daily (P < 0.001). D0870 is approximately 10-fold more active than fluconazole. It is a promising treatment for coccidioidomycosis, which warrants further testing.
authors.affiliation: Dept. of Medicine, Santa Clara Valley Medical Center, San Jose, CA 95128-2699.
authors.forename: K V
authors.initials: KV
authors.lastname: Clemons
authors.forename: D A
authors.initials: DA
authors.lastname: Stevens
mesh_terms: D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D003045:Coccidioides / Q000302:isolation & purification; D003047:Coccidioidomycosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D008099:Liver / Q000382:microbiology; D008168:Lung / Q000382:microbiology; D051379:Mice; D008815:Mice, Inbred Strains; D013154:Spleen / Q000382:microbiology; D013237:Stereoisomerism; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D000935:Antifungal Agents; D014230:Triazoles; C058219:ICI 195739; D015725:Fluconazole